Extended Data Fig. 5: αCD45-IL15 displays altered biodistribution compared to non-targeted IgG-IL15.
From: Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity
a-g, AF647-labeled αCD45-IL15 or IgG-IL15 was dosed (10 µg) intratumorally in established MC38 tumors 24 hours prior to flow cytometry analysis (n = 4 mice/group). Shown are a, Tumor cell-type specific biodistribution by percentage (left) or MFI (right). b, Representative tumor images from the experiment described in Fig. 2a. Scale bar, 50 µm. c, Representative contour plot of AF647 signal on TDLN CD45+ cells. d, Representative TDLN images from the experiment described in Fig. 2a. Scale bar, 200 µm. e, Representative TDLN images from the experiment described in Fig. 2a. Scale bar, 10 µm. f, TDLN cell-type specific biodistribution by percentage (left) or MFI (right). g, Compartment specific biodistribution by MFI (left) or percentage (right). h, AF647-labeled αCD45-IL15 was dosed (10 µg) peritumorally (s.c. at the tail-base) 24 hours prior to flow cytometry analysis (n = 4 mice/group). For all plots, shown are mean ± s.d of the stated replicates. P values were determined by two-sided t-test, one-way, or two-way ANOVA followed by Tukey’s multiple comparison test. Exact P values are denoted in the figure; “ns” = not significant (P > 0.05).
